0000000000933437

AUTHOR

Cinzia Cordioli

showing 10 related works from this author

A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia

2021

The prevalence of trigeminal neuralgia (TN) in patients with Multiple Sclerosis (MS) is higher than in the general population and its management can be particularly challenging due to a number of reasons including high recurrence rates, lack of MS-specific treatment guidelines and uncertainties about pain pathophysiology. Aim of this cross-sectional, multicentre survey was to gather information on the current treatment modalities and options of MS-related TN across 23 Italian MS centres. Initial medical management (carbamazepine or oxcarbazepine) of MS-related TN was fairly homogeneous throughout Italian centres. The most commonly available surgical procedure was microvascular decompression…

medicine.medical_specialtyMultiple Sclerosismultiple sclerosis; trigeminal neuralgiaCross-sectional studymedicine.medical_treatmentPopulationMicrovascular decompressionHealth Services Accessibility03 medical and health sciences0302 clinical medicineRetrospective StudieTrigeminal neuralgiaMultiple SclerosimedicineHumans030212 general & internal medicineIntensive care medicineeducationOxcarbazepineRetrospective StudiesCross-Sectional Studieeducation.field_of_studybusiness.industryMultiple sclerosisRetrospective cohort studyTrigeminal Neuralgiamedicine.diseaseCross-Sectional StudiesTreatment OutcomeItalyNeurologyMulticenter surveyNeurology (clinical)businessMultiple Sclerosis; Trigeminal neuralgia; Cross-Sectional Studies; Health Services Accessibility; Humans; Italy; Retrospective Studies; Treatment Outcome; Multiple Sclerosis; Trigeminal NeuralgiaTrigeminal neuralgia030217 neurology & neurosurgeryHumanmedicine.drugJournal of the Neurological Sciences
researchProduct

mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis

2021

Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. A novel coronavirus, namely SARS-CoV-2, has been recently responsible for the highly infectious disease referred as COVID-19, rapidly spreading all over the world. Many vaccines have been developed to control COVID-19 pandemic, including the mRNA vaccines Pfizer/BioNTech (BNT162b2) and Moderna (mRNA1273).1 The vaccination of people with MS (pwMS) has been recommended by several national and international MS societies. However, effectiveness and safety of anti-COVID-19 mRNA vaccines in MS need to be confirmed. The aim of this study was to evaluate the short-term risk of clinical relapses in pwMS in …

Pediatricsmedicine.medical_specialtyeducation.field_of_studyExpanded Disability Status ScaleCoronavirus disease 2019 (COVID-19)business.industryMultiple sclerosisCOVID-19; multiple sclerosis; neuroimmunologyPopulationCOVID-19neuroimmunologymedicine.diseasemultiple sclerosisVaccinationPsychiatry and Mental healthInfectious disease (medical specialty)multiple sclerosiPandemicmedicineSurgeryObservational studymultiple sclerosis neuroimmunology COVID-19Neurology (clinical)businesseducation
researchProduct

Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group

2020

Background: Worldwide multiple sclerosis (MS) centers have coordinated their efforts to use data acquired in clinical practice for real-world observational studies. In this retrospective study, we aim to harmonize outcome measures, and to evaluate their heterogeneity within the Rising Italian Researchers in MS (RIReMS) study group. Methods: RIReMS members filled in a structured questionnaire evaluating the use of different outcome measures in clinical practice. Thereafter, thirty-four already-published papers from RIReMS centers were used for heterogeneity analyses, using the DerSimonian and Laird random-effects method to compute the between-study variance (τ2). Results: Based on questionna…

AdultLongitudinal studymedicine.medical_specialtyHarmonizationOutcome measuresMultiple sclerosisOutcome measure03 medical and health sciences0302 clinical medicineHarmonization; Multiple sclerosis; Outcome measures; Real worldmedicineHumansMultiple sclerosi030212 general & internal medicineAge of OnsetAgedRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosisOutcome measuresRetrospective cohort studyReal worldGeneral MedicineVariance (accounting)medicine.diseaseNeurologyItalyHarmonizationFamily medicineObservational studyFemaleNeurology (clinical)business030217 neurology & neurosurgeryHarmonization; Multiple sclerosis; Outcome measures; Real world; Adult; Age of Onset; Aged; Female; Humans; Italy; Retrospective Studies; Multiple Sclerosis
researchProduct

Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study

2019

Abstract Background The prevalence of trigeminal neuralgia (TN) in Multiple Sclerosis (MS) patients is higher than in the general population and its management can be particularly challenging. Our aim is to describe the characteristics, treatment and prognostic factors of MS-related TN in a retrospective multicentre study. Methods Neurologists members of the RIREMS group (Rising Researchers in MS) enrolled MS patients with a TN diagnosis and filled out a spreadsheet comprising their clinical data. Results Population consisted of 298 patients. First-choice preventive treatments were carbamazepine and oxcarbazepine. A surgical procedure was performed in 81 (30%) patients, most commonly gamma …

Pediatricsmedicine.medical_treatmentmultiple sclerosismicrovascular decompression surgerytime factors0302 clinical medicineRadiofrequency thermocoagulationTrigeminal neuralgiaMultiple SclerosiOutcome Assessment Health Careitalymiddle agedpain030212 general & internal medicineOxcarbazepinehumanseducation.field_of_studytrigeminal neuralgiaadultDisability; Multiple Sclerosis; Pain; Trigeminal neuralgiaradiosurgeryGeneral MedicineAnalgesics Non-Narcotichealth carefollow-up studiesSettore MED/26 - NEUROLOGIAagedretrospective studiesfemaleNeurologydisability; multiple sclerosis; pain; trigeminal neuralgia; adult; aged; analgesics non-narcotic; female; follow-up studies; humans; italy; male; microvascular decompression surgery; middle aged; multiple sclerosis; radiosurgery; retrospective studies; severity of illness index; sex factors; time factors; trigeminal neuralgia; neurosurgical procedures; outcome assessment health careanalgesicsTrigeminal neuralgiamedicine.drugmedicine.medical_specialtyMultiple SclerosisPopulationPainMicrovascular decompression03 medical and health sciencesmalemedicineseverity of illness indexeducationoutcome assessmentDisabilitybusiness.industryMultiple sclerosisCarbamazepinemedicine.diseaseneurosurgical proceduresDiscontinuationsex factorsdisabilitynon-narcoticNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.

2013

Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologist's therapeutic attitude towards relapse management, which is the aim of this study. Neurologists from 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple sclerosis relapses. The questionnaire requested a guided description of the relapse's clinical characteristics and an indication of the prescribed therapy, supported with up to 3 out of 20 suggested reasons. Over 3 months, 368 questionnaires were collected. Median percentage (%) of 21 relapses resulting in a …

MalePediatricsNeurologyCross-sectional studymulti center studyAdrenal Cortex HormoneAdrenal Cortex HormonesRecurrenceSurveys and QuestionnairesMultiple SclerosiCorticosteroidSurveys and QuestionnaireRelapseSurveyNeuroradiologyGeneral MedicineMiddle AgedManagementPsychiatry and Mental healthMethylprednisoloneItalyNeurologyPsychiatry and Mental Healthmultiple sclerosiSettore MED/26 - NeurologiaFemaleNeurosurgerymedicine.drugHumanAdultmedicine.medical_specialtyMultiple SclerosisDermatologyMethylprednisolonemedicineHumansMedical prescriptionCross-Sectional Studietherapybusiness.industryMultiple sclerosismedicine.diseaseManagement of multiple sclerosisCross-Sectional StudiesHealth Care SurveyHealth Care SurveysPhysical therapyNeurology (clinical)business2708
researchProduct

Informing MS patients on treatment options: a consensus on the process of consent taking

2020

Abstract\ud In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient’s empowerment in the decision-making process.\ud Aims\ud The aims of our project were to review the strategies used by Italian MS specialists to inform patients about treatment options and to design a multicentre shared document that homogenizes the information about disease-modifying treatment (DMTs) and the procedure of taking informed consent in clinical practice.\ud Results\ud The new resource, obtained by consensus among 31 neurologists from 27 MS Centres in Italy with the…

medicine.medical_specialtyConsensusProcess (engineering)media_common.quotation_subjectDermatologyDisease modifying treatment; Informed consent; Multiple sclerosisMultiple sclerosis03 medical and health sciences0302 clinical medicineResource (project management)Informed consentDisease modifying treatmentmedicineHumans030212 general & internal medicineInformed consentEmpowermentmedia_commonPhysician-Patient Relationsbusiness.industryTreatment optionsGeneral MedicineClinical PracticePsychiatry and Mental healthItalyFamily medicineDisease modifying treatment; Informed consent; Multiple sclerosis; Consensus; Humans; Italy; Physician-Patient Relations; Informed Consent; Multiple SclerosisSettore MED/26 - NeurologiaNeurology (clinical)Decision processbusiness030217 neurology & neurosurgery
researchProduct

Clinical activity after fingolimod cessation: Disease reactivation or rebound?

2018

Background and purpose There is debate as to whether the apparent rebound after fingolimod discontinuation is related to the discontinuation itself or whether it is due to the natural course of highly active multiple sclerosis (MS). Our aim was to survey the prevalence of severe reactivation and rebound after discontinuation of fingolimod in a cohort of Italian patients with MS. Methods Patients with relapsing-remitting MS who were treated with fingolimod for at least 6 months and who stopped treatment for reasons that were unrelated to inefficacy were included in the analysis. Results A total of 100 patients who had discontinued fingolimod were included in the study. Fourteen patients (14%…

AdultMalemedicine.medical_specialtyAdolescentDiseaseCohort StudiesMultiple sclerosisImmunosuppressive AgentYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineRecurrenceInternal medicineHumansMedicine030212 general & internal medicineFingolimod; Multiple sclerosis; Reactivation; Rebound; Neurology; Neurology (clinical)Natural courseReboundFingolimod Hydrochloridebusiness.industryMultiple sclerosisFingolimodmedicine.diseaseReactivationMagnetic Resonance ImagingFingolimodDiscontinuationItalyWithholding TreatmentNeurologymultiple sclerosiCohortFemaleNeurology (clinical)Cohort StudiebusinessImmunosuppressive Agents030217 neurology & neurosurgeryHumanmedicine.drug
researchProduct

Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.

2022

ObjectiveAssessing the risk of clinical and radiological reactivation during pregnancy and post partum in women with multiple sclerosis (MS) treated with natalizumab (NTZ) throughout pregnancy (LONG_EXP) compared with women interrupting treatment before (NO_EXP) and within >−30 days and ≤90 days from conception (SHORT_EXP), and describing newborns’ outcomes.MethodsMaternal clinical and radiological outcomes and obstetric and fetal outcomes were retrospectively collected and compared among groups (NO_EXP, SHORT_EXP, LONG_EXP). Predictors of clinical and radiological reactivation were investigated through univariable and multivariable analysis.Results170 eligible pregnancies from 163 women…

Psychiatry and Mental healthSettore MED/26 - NEUROLOGIAobstetricsmultiple sclerosiobstetricSurgeryNeurology (clinical)MRI; multiple sclerosis; obstetricsSettore MED/26multiple sclerosisMRIJournal of neurology, neurosurgery, and psychiatry
researchProduct

To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy

2016

OBJECTIVE: To retrospectively analyze the effect of plasma exchange (PLEX; yes = PLEX+ , no = PLEX- ) and steroids administration timing (prophylactically [proST] or therapeutically [therST]) on the longitudinal clinical course of patients with natalizumab-related progressive multifocal leukoencephalopathy (PML) and full-blown immune reconstitution inflammatory syndrome (PML-IRIS). METHODS: Clinical and radiological data of 42 Italian patients with PML were analyzed. Patient's data are available until 12 months after PML diagnosis. PLEX and steroids treatment as time-dependent covariates were entered in: (1) a Cox model to investigate their impact on full-blown PML-IRIS latency; (2) an anal…

AdultMaleAdult; Databases Factual; Disability Evaluation; Female; Humans; Immune Reconstitution Inflammatory Syndrome; Leukoencephalopathy Progressive Multifocal; Male; Plasma Exchange; Retrospective Studies; Steroids; Young Adult; Neurology; Neurology (clinical)Adult; Databases Factual; Disability Evaluation; Female; Humans; Immune Reconstitution Inflammatory Syndrome; Leukoencephalopathy Progressive Multifocal; Male; Plasma Exchange; Retrospective Studies; Steroids; Young AdultDatabases FactualPlasma ExchangeLeukoencephalopathy Progressive MultifocalProgressive MultifocalDatabasesDisability EvaluationYoung AdultNeurologyLeukoencephalopathyImmune Reconstitution Inflammatory SyndromeRetrospective StudieHumansSteroidsFemaleSettore MED/26 - NeurologiaNeurology (clinical)SteroidFactualRetrospective StudiesHuman
researchProduct

The still under-investigated role of cognitive deficits in PML diagnosis

2017

Background: Despite cognitive deficits frequently represent the first clinical manifestations of Progressive Multifocal Leukoencephalopathy (PML) in Natalizumab-treated MS patients, the importance of cognitive deficits in PML diagnosis is still under-investigated. The aim of the current study is to investigate the cognitive deficits at PML diagnosis in a group of Italian patients with PML. Methods: Thirty-four PML patients were included in the study. The demographic and clinical data, the lesion load and localization, and the longitudinal clinical course was compared between patients with (n = 13) and without (n = 15) cognitive deficit upon PML suspicion (the remaining six patients were asy…

0301 basic medicinecognitionmedicine.medical_specialtyPediatricscognition; italian database; natalizumab; neuropsychological impairment; progressive multifocal leukoencephalopathy; neurology (clinical); neurology; immunology; immunology and allergy; natalizumab; cognition; neuropsychological impairment; italian databaseNeurologySettore MED/17 - Malattie InfettiveAsymptomaticApraxiaprogressive multifocal leukoencephalopathyimmunology03 medical and health sciences0302 clinical medicinenatalizumabitalian databasemedicineDementiaimmunology and allergyPsychiatryCognitive deficitneurology (clinical)Progressive multifocal leukoencephalopathyneurologyNeuropsychologyCognitionProgressive multifocal leukoencephalopathy Natalizumab Cognition Neuropsychological impairment Italian databasemedicine.disease030104 developmental biologyCognition; Italian database; Natalizumab; Neuropsychological impairment; Progressive multifocal leukoencephalopathyCognition Italian database Natalizumab Neuropsychological impairment Progressive multifocal leukoencephalopathyCognition; Italian database; Natalizumab; Neuropsychological impairment; Progressive multifocal leukoencephalopathy; Immunology and Allergy; Immunology; Neurology; Neurology (clinical)Settore MED/26 - Neurologiamedicine.symptomPsychologyneuropsychological impairment030217 neurology & neurosurgery
researchProduct